<DOC>
	<DOCNO>NCT00515112</DOCNO>
	<brief_summary>The purpose study determine whether prostate cancer growth slow patient receive AndrogelÂ® 1 % 10 gram dose .</brief_summary>
	<brief_title>Testosterone Replacement Men With Non-Metastatic Castrate Resistant Prostate Cancer</brief_title>
	<detailed_description>The primary objective study determine effect testosterone replacement time disease progression time clinical cancer progression . The secondary objective describe effect testosterone replacement patient-reported quality life ( FACT-P , FACT-fatigue specific measure Expanded Prostate Cancer Index ( EPIC ) : Sexual Hormonal Assessments ) , hand-grip strength ; describe change total testosterone , free testosterone , PSA level ; explore AR level circulate tumor cell marker treatment benefit .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Prostate cancer Patient must receive primary definitive local therapy prostate ( surgery and/or radiotherapy ) Patient surgically pharmacologically castrate least 6 month prior start study Patient must previous trial antiandrogen therapy Patient must rise PSA No evidence distant metastatic disease ECOG performance status &lt; 2 Age &gt; 18 year Patients must normal hepatic function Patients history previous cytotoxic therapy radionuclide therapy ( rhenium , strontium , samarium ) Patients may receive investigational agent Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , uncontrolled cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Patients receive renal dialysis Patients significant pulmonary disease receive chronic pulse steroid therapy within last 3 month prior randomization exclude Patients know hypersensitivity AndroGel ingredient , include testosterone chemically synthesize soy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>testosterone replacement</keyword>
	<keyword>AndroGel</keyword>
	<keyword>prostatic cancer</keyword>
	<keyword>prostatic neoplasm</keyword>
</DOC>